Pheast Therapeutics’ PHST001, targeting CD24 to enhance immune response against tumors, received FDA Fast Track Designation for ovarian cancer treatment. CD24, a cell surface protein identified as a macrophage checkpoint, hinders cancer cell clearance by engaging Siglec-10, an inhibitory receptor on macrophages. This discovery by Dr. Amira Barkal and team at Pheast promises a novel approach to combatting ovarian cancer by leveraging the innate immune system’s ability to target tumors.
Read more from finance.yahoo.com